FDA’s Popular CMMI Maturity Model Appraisal Program Soldiers On In Spite Of COVID-19
Virtual CMMI appraisals could be on the way
• By Shawn M. Schmitt
Generate a summary of this article
Listen to this article
The Case for Quality Voluntary Improvement Program, run jointly by the US FDA and the Medical Device Innovation Consortium, is leaning heavily on remote quarterly checkpoint meetings with participants in lieu of on-site appraisals. CFQ VIP aims to elevate product, manufacturing and process quality at device firms by assessing the companies against a modified version of the Capability Maturity Model Integration (CMMI) framework.
As the world continues to grapple with the coronavirus pandemic, a popular program that aims to assess the manufacturing maturity of medical device firms is soldiering on.
The Case for Quality Voluntary Improvement Program – or CFQ VIP – is run jointly by the US Food...
Keep up with the top medtech business and regulatory news.
Medtech Insight brings you interviews and analysis, on the go.
In this week’s Digital Health Roundup, Medtech Insight’s Ryan Nelson highlights Click Therapeutics’ FDA-cleared digital therapeutics (DTx) for depression and Sinaptica Therapeutics’ personalized neuromodulation for Alzheimer’s patients. Marion Webb discusses her interview with MindMaze’s John Krakauer on their gaming-focused DTx to help people recover from serious brain injuries. Elizabeth Orr introduces new voting members of the new Digital Health Advisory Committee and Natasha Barrow discusses Hello Heart’s new symptom-tracking feature in their heart-focused app.
This week, Establishment Labs Holdings announced the FDA gave it premarket approval for Motiva breast implant, Cologuard lands FDA approval for Cologuard Plus and GE HealthCare gets FDA nod for a new imaging agent. The FDA announces another expansion for TAP into ophthalmology and radiology. The AAMI and CTA will join forces to develop standards for AI and ML-enabled health care products.
Children with biliary atresia (BA) exhibited neurodevelopmental deficits and increased autism traits, with earlier surgery linked to better general neurodevelopment.
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 40 documents have been posted on the tracker since its last update.
This week, Establishment Labs Holdings announced the FDA gave it premarket approval for Motiva breast implant, Cologuard lands FDA approval for Cologuard Plus and GE HealthCare gets FDA nod for a new imaging agent. The FDA announces another expansion for TAP into ophthalmology and radiology. The AAMI and CTA will join forces to develop standards for AI and ML-enabled health care products.
Children with biliary atresia (BA) exhibited neurodevelopmental deficits and increased autism traits, with earlier surgery linked to better general neurodevelopment.